China’s NHSA has added Leqembi (lecanemab) to a new Commercial Insurance Innovative Drug List effective Jan. 1, 2026, enabling commercial insurers to negotiate coverage and design insurance products for the therapy and potentially narrow the gap between NRDL reimbursement and innovative drugs. Eisai, which launched Leqembi in China’s private market in June 2024 and estimates about 17 million people with MCI or mild Alzheimer’s in 2024, will lead insurer discussions — a development that could substantially expand access and uptake in China if coverage and pricing agreements are reached. For BioArctic, co‑developer of lecanemab with Nordic commercialization rights and entitlement to sales milestones and royalties, the listing creates a clear pathway to incremental China-derived revenue, although the timing and magnitude depend on commercial insurance negotiations and implementation.
Eisai announced on December 9, 2025 that Leqembi (lecanemab) has been added to China’s new Commercial Insurance Innovative Drug List, a policy effective January 1, 2026 that enables commercial insurers to negotiate coverage and design products for listed innovative medicines. Eisai launched Leqembi in China’s private market in June 2024 and estimates a 2024 patient pool of 17 million with MCI or mild dementia due to Alzheimer’s, indicating substantial addressable demand if commercial coverage is adopted broadly. BioArctic, which invented lecanemab and retains Nordic commercialization rights, stands to receive sales milestones and global royalties with Eisai responsible for clinical development and commercialization; however, the listing does not equate to NRDL inclusion and revenue realization will depend on insurer negotiations, pricing and product uptake. Leqembi’s regulatory and clinical backdrop is supportive: the drug is approved in 51 countries, under review in nine, Eisai completed a rolling sBLA for a subcutaneous initiation in November 2025 and has ongoing pivotal/ preventive trials (AHEAD 3-45 fully recruited October 2024), creating multiple near- to mid-term catalysts. Primary risks are commercial rather than clinical: the timetable and magnitude of China revenue are contingent on commercial insurance agreements and adoption by payers and patients, so near-term market impact is moderately positive (sentiment score 0.45, market impact score 0.35) but uncertain until insurers disclose coverage terms.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately positive
Sentiment Score
0.45
